Updates

How copper peptides appear on cosmetic ingredient labels — October 16, 2026

How copper peptides (GHK-Cu) show up on a US cosmetic ingredient list: the INCI name, where it sits, and what the label can and can't tell you.

How to read a skincare ingredient label — October 16, 2026

How to read a US cosmetic ingredient list: descending order, the 1% rule, color additives, trade secrets and INCI peptide names, per FDA.

Is a peptide skincare product a cosmetic or a drug? — October 15, 2026

This page is non-clinical. It explains the legal categories and makes no claim about whether any ingredient works.

Register: the product still listed is now shown as "Review incomplete" — October 4, 2026

The one product still named in the Register was shown with a full-pass verdict although one applicable check, Claims, had not been independently confirmed. It is now shown as "Review incomplete", with the confirmed and open checks stated on every page that describes it and a dated review note on which checks rest on secondary evidence. The listing is unchanged. This is not a fail and not a finding of wrongdoing.

Register: one product temporarily removed from the passing list — October 3, 2026

One product was temporarily removed from the Register's passing list on 3 October 2026 while a review of all applicable points is completed. This is not a fail and not a finding of wrongdoing. The earlier assessment and its evidence are preserved, and the product will be listed again only after a complete review supports it. The Register now lists one product.

Correction: UK actions page - the MHRA alert's address, dose-knob and batch wording, and the GPhC conditions — October 2, 2026

The UK enforcement page linked an MHRA alert at an address that now returns "not found," and its Birmingham pharmacy row described the faulty-pen finding, the batch number and the General Pharmaceutical Council's conditions more loosely than the sources do. The row now uses the MHRA's current address and closely follows its statements (all five pens identified to date faulty, the dose knob coming off in all but one; batch D873576 legitimate for genuine 7.5mg pens), links the GPhC's own enforcement summary, which states the condition that the pharmacy must not obtain, sell or supply prescription only medicines or medical devices, and the reference list now names only the outlets whose reports were checked. No entry was added or removed.

Correction: the Register's commercial-relationship statement now says only what is recorded today — October 1, 2026

The Register's "Commercial relationships today" statement said that no brand has paid to be assessed or listed. That describes history the page cannot document, so it now says only what the Register records today: no commercial relationship is recorded for any product currently listed. The page also states the conditions for any future relationship: it could be added only after a product has independently passed the published standard; payment cannot start, speed up, change or preserve an assessment or listing; a product that later fails is removed or updated whatever its commercial status; click counts are aggregate only, with no visitor profiles and nothing sent to a partner; and commission is never evidence that a product is better or safer. The same sentence was removed from the Register summary and the two product listing pages ("none was contacted before publishing this" and "disclosed ... before it happens"), for the same reason. No result or listing changed.

Correction: CagriSema's regulatory status now says only what the sources support — October 1, 2026

The Cagrilintide / CagriSema page, its Library card and its tracker row said the application was "under FDA review", that a decision "could land at any time", and that a head-to-head result against tirzepatide rested on secondary coverage. They now say Novo Nordisk reports it filed an application, FDA has not approved CagriSema, and no FDA decision has been announced as of 1 October 2026; the head-to-head result is sourced to Novo's own February 2026 report. No grade changed.

Correction: kisspeptin studies described more precisely — October 1, 2026

The Kisspeptin page, its Library card and tracker row called both human studies "controlled" and described the 2017 study as double-blind and placebo-controlled with intravenous dosing. PubMed's records show the 2014 IVF study gave kisspeptin-54 at one of four doses with no comparison group described, and index the 2017 study as a randomized controlled trial (indexed as double-blind) comparing kisspeptin with vehicle. The abstracts do not state the route of administration, so the page no longer does. The same wording was removed from the key points, the consumer-products section and the "first controlled human demonstration" sentence; only the 2017 paper is described as randomized and vehicle-controlled. No grade changed.

Correction: why Factrel and Lutrepulse were discontinued is not recorded by FDA — October 1, 2026

The Gonadorelin page, its Library card and tracker row said both branded products were withdrawn for commercial reasons, based on secondary pharmacy references. FDA's Drugs@FDA records show both as discontinued without stating a reason, so the pages now say only that. No grade changed.

Correction: gonadorelin's discontinuation no longer attributed to commercial reasons on the leuprolide page — October 1, 2026

The Leuprolide page said gonadorelin's branded products were discontinued for commercial reasons, in its standfirst and in a comparison section. FDA's Drugs@FDA records list Factrel and Lutrepulse as discontinued without stating a reason, so both sentences now say that. Nothing else on the page changed. No grade changed.

Correction: rusfertide (Mimrylo) page's application number and approval details — October 1, 2026

The Rusfertide page gave the application number as NDA 219818; FDA's approval letter and Drugs@FDA record show NDA 220605. It also called the molecule a "24-amino-acid peptide", said the application was filed in January 2026 and accepted in March, named Protagonist alongside Takeda as approval holder, described Breakthrough Therapy and Fast Track designations (FDA's approval letter and news release mention neither), and called this the first FDA approval of a hepcidin-mimetic drug in any indication. The page now follows FDA's records: a synthetic cyclic peptide per the label, application received 29 December 2025 and reviewed under Priority Review, approval granted to Takeda Pharmaceuticals America on 28 August 2026, and FDA's own wording that it is the first approved treatment for polycythemia vera that mimics hepcidin. Label dose figures were removed. The approval date and indication were already correct. No grade changed.

Update: insulin efsitora alfa (Onswik) is now FDA-approved — October 1, 2026

The Insulin Efsitora Alfa page, its Library card and its teaser said the drug was not yet approved in the US or EU and that an FDA decision was pending. FDA's 2026 novel drug approvals list and the FDA-approved prescribing information show Onswik (insulin efsitora alfa-gobe) approved on 23 September 2026 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, with a limitation of use: not recommended in type 1 diabetes because of increased risk of severe hypoglycemia. The page also said NICE had backed NHS funding ahead of MHRA approval; NICE's project page records final draft guidance on 20 August 2026 and lists the appraisal as in development, so that description was removed. The EU position is stated as the CHMP's positive opinion of 25 June 2026. No grade changed.

Correction: FDA's 503B proposal on semaglutide and tirzepatide described as a proposal, not a closed pathway — October 1, 2026

The Semaglutide, Tirzepatide and Semaglutide vs Tirzepatide pages said the compounding pathway "is closing", that FDA found no clinical need "once the shortage ended", and that the proposal, if finalized, would close the compounding pathway's legal basis. FDA's 1 May 2026 Federal Register notice (91 FR 23431) is a proposal that tentatively finds no clinical need for outsourcing facilities to compound semaglutide, tirzepatide or liraglutide from bulk substances; it says shortages are not themselves a clinical need, applies to section 503B outsourcing facilities only, and FDA said it will consider comments before a final determination. The pages now say that and that the proposal is not final. No grade changed.

Correction: kisspeptin page's route-of-administration note and summary field — October 1, 2026

The kisspeptin correction note said the abstracts of both human studies do not state the route of administration. The 2014 IVF study's abstract states a single subcutaneous injection of kisspeptin-54, as the page's study description already said; the 2017 abstract states no route. The page's summary field still read "IV/subcutaneous", which no source supports for the 2017 study. The note now says so and the summary field no longer lists a route. No grade changed.

Correction: remaining "closing" wording on FDA's 503B proposal, tirzepatide shortage dates and trial-evidence phrasing — October 1, 2026

Further to the earlier 503B correction: the Semaglutide and Tirzepatide summary lines, key points, Library cards and tracker rows no longer say the compounding channel is "being formally closed" or "restricted"; they say FDA has proposed, not finalized, not to list the drug on the 503B bulks list (announced 30 April 2026, published in the Federal Register 1 May 2026). The Semaglutide vs Tirzepatide section heading "same situation, same deadline" now reads "same situation, same proposal" (the notice sets no deadline; comments were due 30 June 2026, extended to 30 July 2026) and a sentence claiming no difference in legal exposure was removed. Tirzepatide's shortage dates now follow FDA's declaratory order: removed from the shortage list 2 October 2024, determined resolved again 19 December 2024. The Federal Register notices and the declaratory order are linked as references. Separately, wording about missing randomized-trial evidence on the HCG, Gonadorelin and kisspeptin-vs-gonadorelin-vs-hCG pages now states only what each page cites, and an unsupported phrase ("as an alternative to conventional triggers") was removed from the Kisspeptin study description. No grade changed.

Correction: insulin efsitora alfa's peak-to-trough figure and icodec page's efsitora status — October 1, 2026

The Insulin Efsitora Alfa page gave a peak-to-trough ratio of about 1.14 and said levels vary by well under 15% across the week. The FDA-approved Onswik label (section 12.3) gives a peak-to-trough ratio of 1.16, so the page now says about 1.16 and drops the percentage. Lilly's "fourth worldwide approval" wording was removed so the EU status rests on EMA's own page (CHMP positive opinion of 25 June 2026). The Insulin Icodec page said efsitora alfa remained without a final US or EU decision; it now says the FDA approved it on 23 September 2026 for adults with type 2 diabetes. No grade changed.

Clarification: what was and was not wrong in the rusfertide (Mimrylo) correction — October 1, 2026

The earlier rusfertide correction listed several items. FDA's approval letter contradicts only "filed in January 2026" (it records the application as received on 29 December 2025). Acceptance in March 2026 and Priority Review are consistent with FDA's record and Takeda's 2 March 2026 announcement. The "24-amino-acid" figure was wrong: the label's chemical name lists 17 amino-acid residues. Breakthrough Therapy and Fast Track designations were removed because FDA's records of this approval do not state them, not because they were shown to be wrong; Takeda's announcement lists them. No grade changed.

Correction: attribution of rusfertide facts, tirzepatide wording, HCG and gonadorelin off-label text — October 1, 2026

Rusfertide: the clarification said acceptance in March 2026 and Priority Review were consistent with FDA's record. Priority Review is stated in FDA's news release and the orphan designation in FDA's approval letter; the acceptance of the application in March 2026 appears only in Takeda's 2 March 2026 announcement. The label's chemical name lists 17 amino-acid residues (the first note said the label gives no count). Tirzepatide: a box saying grey-market vials "carry the same legal exposure as unapproved-drug sale" now states FDA's position that unapproved versions of GLP-1 drugs do not undergo FDA review before marketing, and the key question now refers to FDA's 503B proposal (not final). Semaglutide and tirzepatide shortage-resolution dates are now linked to FDA's declaratory orders (21 February 2025 and 19 December 2024). HCG: off-label dose figures removed. Gonadorelin: an unsourced comparison with how often HCG is used was removed. No grade changed.

Correction: semaglutide page wording on vials sold outside a prescription — October 1, 2026

The semaglutide page's box on vials sold outside a pharmacy-dispensed prescription said they sit "outside the approved-drug framework regardless of purity claims." It now uses FDA's own statement that unapproved versions of GLP-1 drugs, including semaglutide, do not undergo FDA's review for safety, effectiveness and quality before they are marketed, with a link to that FDA page. No other facts on the page changed.

Correction: the Register's description of its commercial relationships was unclear — September 30, 2026

The Register's "What the Register is — and isn't" section called it "a shop window with a doorman", said "we're a retailer with a standard", and said "when we eventually earn commission on a sale, we say so". Read literally, that suggested the Register sells products or earns, or is about to earn, commission. It does not: the Register sells nothing, carries no advertising, has no affiliate or commission arrangement and takes no payment from any brand, and its links to listed brands carry no referral code. The section, and the matching wording on the How we make money, Terms and About pages and in the Library page on why this site takes no vendor payment for placement, now say so directly. They also state that any future affiliate or commission link would carry a visible "we may earn a commission" notice and could be added only to a product that has already passed, and that commercial relationships affect neither an evidence grade nor a Register result. No result or listing changed.

2 new Library pages: a genuinely new hemophilia drug class, and the only treatment for an ultra-rare enzyme disease — September 26, 2026

Concizumab & Marstacimab (Alhemo & Hympavzi) covers two independently developed monoclonal antibodies that treat hemophilia A and B by blocking tissue factor pathway inhibitor rather than replacing or bridging around a missing clotting factor — both reached the US market within three months of each other in late 2024, and both have since expanded to cover more patients, but concizumab's road there included a real, year-long worldwide clinical hold in 2020 after thrombotic events in three trial patients. Velmanase Alfa (Lamzede) is the only approved treatment anywhere for alpha-mannosidosis, an ultra-rare lysosomal storage disease — its pivotal trial hit a clean, statistically significant biomarker endpoint but fell short of significance on its motor-function endpoint, and the EU approved it under an exceptional-circumstances pathway nearly five years before the FDA followed. The Library now stands at 199 ingredient pages.

3 new Library pages: a third rapid-acting insulin, a third anti-C5 antibody, and the first hypophosphatasia treatment — September 25, 2026

Insulin Glulisine (Apidra) completes this site's rapid-acting insulin cluster alongside insulin lispro and insulin aspart — a third, independently engineered analog approved 2004, the only one formulated without zinc, with a real 70% US list-price cut in 2024 rather than any pricing scandal. Crovalimab (Piasky) completes the anti-C5 cluster alongside eculizumab and ravulizumab — a third antibody against the same target, approved 2024 and engineered for once-monthly home self-injection, matching eculizumab in two head-to-head Phase 3 trials, with a genuine, mechanism-specific drug-interaction risk when switching from eculizumab. Asfotase Alfa (Strensiq) is the first treatment for hypophosphatasia ever approved, in 2015, with a real survival benefit documented against historical controls and a roughly $285,000-a-year price that a UK cost regulator initially refused to cover for adults before a managed-access deal followed. The Library now stands at 197 ingredient pages.

2 new Library pages: two opposite fixes for hemophilia A, and the first bispecific antibody built for the eye — September 24, 2026

Efanesoctocog Alfa & Emicizumab (Altuviiio & Hemlibra) covers two real, FDA-approved hemophilia A drugs that solve the same missing-factor-VIII problem in opposite ways: efanesoctocog alfa is an engineered factor VIII replacement built to break the von Willebrand factor half-life ceiling that limited every factor VIII product before it, approved 2023 on the Phase 3 XTEND-1 trial; emicizumab is a bispecific antibody that skips factor VIII entirely, approved 2017 for patients with factor VIII inhibitors and expanded in 2018 to all hemophilia A patients, carrying a real boxed warning for a drug interaction identified in its own pivotal trial. Faricimab (Vabysmo) completes this site's anti-VEGF eye-disease cluster alongside aflibercept — the first bispecific antibody ever approved for the eye, matching aflibercept's vision outcomes with fewer injections across four Phase 3 trials since its 2022 approval, alongside a real, still-monitored post-marketing eye-inflammation safety signal. The Library now stands at 194 ingredient pages.

2 new Library pages: the original anti-C5 antibody duo, and the one oral drug in the HAE cluster — September 23, 2026

Eculizumab & Ravulizumab (Soliris & Ultomiris) covers the antibody drugs this site's own pegcetacoplan and zilucoplan pages already reference as "the antibody comparator" — the first monoclonal antibody approved against complement C5 (2007), its engineered successor built for 8-weekly instead of 2-weekly infusions, and the real legal record behind both: an SEC bribery settlement, a $125 million investor settlement, and 2024's first biosimilars after 17 years of exclusivity. Berotralstat (Orladeyo) completes this site's five-drug hereditary angioedema cluster with its one genuinely different format — a once-daily oral capsule, approved 2020 as the first oral HAE prophylactic of any kind, on a real placebo-controlled Phase 3 trial. The Library now stands at 192 ingredient pages.

2 new Library pages: a first-in-class hepcidin mimetic, and Lilly's rival to insulin icodec — September 22, 2026

Rusfertide (Mimrylo) is a genuinely new mechanism for this site: a synthetic peptide that mimics hepcidin, the body's own iron-regulating hormone, to control the excess red blood cell production behind polycythemia vera — approved 28 August 2026 after the placebo-controlled Phase 3 VERIFY trial found a 76.9% response rate versus 32.9% on placebo. Insulin efsitora alfa (Onswik) is Eli Lilly's answer to this site's insulin icodec page, reaching once-weekly dosing through an antibody Fc-fusion rather than icodec's albumin-binding chemistry; its five-trial QWINT program is complete, but a CHMP positive opinion in the EU (June 2026) still awaited European Commission authorization as of this review, and a US FDA decision remained pending. Efsitora alfa's own type 1 diabetes trial found the same kind of hypoglycemia signal that kept icodec off the US label for that indication. The Library now stands at 190 ingredient pages.

Quebec runs its own separate Wegovy reimbursement review, apart from the federal one — and has said no twice — September 22, 2026

This site's Canadian insurance page now covers a second, provincial-level Wegovy story alongside the federal one: Quebec's own drug-evaluation body, INESSS, recommended against reimbursing Wegovy twice in 2025 — once for general obesity (the Health Minister formally declined to list it, March 2026) and once for a narrower heart-attack/stroke-prevention use in patients with existing cardiovascular disease (recommended against, with the minister deferring rather than refusing, December 2025). A separate, still-unlaunched 2024 proposal for a small, monitored pilot program is also covered for context.

2 new Library pages: two more hereditary angioedema antibodies, and a once-weekly echinocandin — September 21, 2026

Lanadelumab (Takhzyro) and garadacimab (Andembry) complete a five-drug hereditary angioedema cluster on this site, each blocking the same bradykinin-generating cascade at a further point upstream. Lanadelumab, approved 2018, blocks plasma kallikrein via a long-acting antibody; the Phase 3 HELP trial found up to an 87% reduction in mean monthly attack rate vs. placebo. Garadacimab blocks Factor XIIa itself, the cascade's actual trigger, one step earlier than any drug already on this site — its VANGUARD trial found an 89.2% attack-rate reduction, and it was approved in Australia, the UK, EU, Japan and Switzerland before the FDA cleared it in June 2025. Separately, rezafungin (Rezzayo) is a fourth echinocandin antifungal, chemically modified from anidulafungin for a much longer half-life that allows once-weekly IV dosing instead of daily — approved 2023 on a single pivotal trial (ReSTORE) and a narrower "limited or no alternative treatment options" label than its class predecessors, after the FDA flagged a nonclinical neurotoxicity signal and required a larger pooled safety database. The Library now stands at 188 ingredient pages.

3 new Library pages: a second radioligand cancer therapy, a fourth engineered G-CSF, and the two original IL-1 blockers — September 20, 2026

Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) is this site's second peptide-receptor radionuclide therapy after Lutathera, targeting PSMA instead of the somatostatin receptor — approved 2022 on a real 4-month survival benefit in the VISION trial, then expanded twice more (2025, 2026) after a genuine 2022-2023 manufacturing shortage got resolved. Efbemalenograstim alfa (Ryzneuta) is a fourth engineered G-CSF joining the filgrastim/pegfilgrastim/sargramostim cluster, approved 2023 on a placebo-controlled trial and a head-to-head noninferiority win against pegfilgrastim. Anakinra (Kineret) and rilonacept (Arcalyst) are the two original FDA-approved interleukin-1 blockers, approved seven years apart by unrelated companies through different mechanisms — a receptor antagonist and a decoy "trap" — that happened to both win approval for the identical ultra-rare disease, DIRA, one week apart in December 2020. The Library now stands at 186 ingredient pages.

2 new Library pages: Orforglipron and Danuglipron, the first non-peptide oral GLP-1 drugs — September 19, 2026

Orforglipron (Foundayo, Eli Lilly) is the first FDA-approved GLP-1 medicine that's a small molecule rather than a peptide — approved 1 April 2026 for chronic weight management on the strength of the 3,127-person ATTAIN-1 trial, with a separate type 2 diabetes trial (ACHIEVE-1) also published; the UK's MHRA approved it for both indications on 10 August 2026, the first approval in Europe, while the EU, Australia and Canada remain pending. Danuglipron is Pfizer's competing small-molecule oral GLP-1 candidate, discovered entirely in-house — its twice-daily formulation showed real, statistically significant weight loss but poor tolerability, and the once-daily reformulation that replaced it was discontinued in April 2025 after a liver-injury signal, two years after a related Pfizer candidate (lotiglipron) was stopped for a similar reason. The Library now stands at 183 ingredient pages.

A new cluster: three FGF21 analogs for MASH liver disease, and the pharma land-grab behind them — September 18, 2026

Efruxifermin, Pegozafermin and Efimosfermin Alfa are three unapproved fibroblast growth factor 21 (FGF21) analogs for MASH-related liver fibrosis and cirrhosis, none previously covered on this site. Efruxifermin's own Phase 2b cirrhosis trial missed its primary endpoint at 36 weeks, then reported a real 96-week cirrhosis-reversal result — real enough for Novo Nordisk to acquire Akero Therapeutics for up to $5.2 billion (closed December 2025). Pegozafermin cleanly met both primary endpoints in its own Phase 2b trial and has held FDA Breakthrough Therapy status since 2023; Roche acquired 89bio for up to $3.5 billion (closed October 2025). Efimosfermin alfa, GSK's once-monthly entry (acquired from Boston Pharmaceuticals for up to $2 billion, closed July 2025), just won FDA Breakthrough and EMA PRIME designations in April 2026 on the smallest completed trial of the three. The Library now stands at 181 ingredient pages.

3 new Library pages: Insulin Detemir, Efpeglenatide, and Dasiglucagon — September 17, 2026

Insulin Detemir (Levemir) was the first engineered insulin to use reversible albumin binding and the only basal insulin ever granted FDA pregnancy category B — Novo Nordisk discontinued it in the US entirely through 2024 anyway, a decision three US senators publicly questioned. Efpeglenatide is a once-weekly GLP-1 drug Sanofi abandoned in 2019 before its own pivotal trial reported a real 27% cardiovascular-risk reduction; its original developer, Hanmi Pharmaceutical, is now pursuing a South Korean obesity approval instead. Dasiglucagon (Zegalogue) completes this site's ready-to-use rescue-glucagon cluster with a chemically restructured analog rather than a reformulation of native glucagon, and is now also in testing as the glucagon half of a dual-hormone artificial pancreas. The Library now stands at 178 ingredient pages.

3 new Library pages: the modern osteoporosis standard this site's own calcitonin page already named, its dual-acting rival, and a third FcRn blocker's first-ever second-disease approval — September 17, 2026

Denosumab (Prolia & Xgeva) completes this site's bone-density cluster alongside teriparatide, abaloparatide and calcitonin — a RANKL-blocking antibody approved 2010 on a real 7,808-patient placebo-controlled trial, with a January 2024 boxed warning added after dialysis-registry data found severe hypocalcemia in 41% of treated patients versus 2% on an oral bisphosphonate. Romosozumab (Evenity) is the one drug in that same cluster that builds new bone and slows its breakdown at once — approved in Japan in January 2019, then delayed in the US by a real 2017 FDA rejection over a cardiovascular signal in its own active-controlled trial, before finally clearing the FDA in April 2019 with a boxed warning. Nipocalimab (Imaavy) joins this site's FcRn-blocker cluster alongside efgartigimod and rozanolixizumab — approved April 2025 for the broadest antibody-positive myasthenia gravis population of the three, then, in August 2026, approved as the first treatment of any kind for a second, unrelated blood disorder: warm autoimmune hemolytic anemia. The Library now stands at 259 ingredient pages.

3 new Library pages: three more investigational entrants in the GLP-1-family obesity race, each built differently — September 17, 2026

Pemvidutide (ALT-801) is a real, investigational GLP-1/glucagon dual agonist from Altimmune, developed in parallel across three separate indications — obesity, MASH, and, uniquely among this site's GLP-1-family pages, alcohol use disorder, where a Phase 2 trial reported a positive topline readout in July 2026. Maridebart Cafraglutide (MariTide) is Amgen's once-monthly obesity drug, built on a genuinely different modality — a GIP-receptor-antagonist antibody conjugated to two GLP-1 peptides — whose published Phase 2 trial found up to 20% weight loss alongside a real, disclosed vomiting and discontinuation problem that led Amgen to redesign its Phase 3 dosing around a slower escalation schedule. Amycretin is Novo Nordisk's single-molecule GLP-1/amylin dual agonist, developed as both a weekly injection and a daily pill, with published Phase 1 efficacy data but the earliest-stage Phase 3 timeline of the three. None of the three is approved anywhere. The Library now stands at 262 ingredient pages.

Health Canada enforcement index grows to 7 actions — September 17, 2026

Three more real, government-sourced actions — Canada Peptide, Rize Fitness, and Maxximus Supplements & Cutting Edge Nutrition — join the existing Health Canada enforcement index, each a public advisory following a seizure of unauthorized injectable peptide products. Six of the seven actions now on the page stopped short of court; Canlab Research remains the one exception.

3 new Library pages: Sebelipase Alfa, Olipudase Alfa, and Pegvaliase — September 16, 2026

Three enzyme-substitution drugs for metabolic diseases this site hadn't covered. Sebelipase Alfa (Kanuma) treats lysosomal acid lipase deficiency and is purified from the eggs of genetically engineered chickens — only the second FDA-approved drug ever made this way. Olipudase Alfa (Xenpozyme) is the only approved treatment for acid sphingomyelinase deficiency (Niemann-Pick B), first cleared in Japan under a pioneer fast-track designation before the FDA followed. Pegvaliase (Palynziq) substitutes a PEGylated bacterial enzyme for phenylketonuria and carries a boxed warning and mandatory REMS program for anaphylaxis — its label only reached adolescents in February 2026. The Library now stands at 175 ingredient pages.

3 new Library pages: the one Fabry enzyme never approved in the US, and a second entrant each in two antibody clusters — September 16, 2026

Agalsidase Alfa (Replagal) completes this site's Fabry disease enzyme cluster alongside agalsidase beta and pegunigalsidase alfa — approved in the EU in 2001, two years before its US rival, and still marketed in more than 70 countries, but the one drug in the cluster never approved by the FDA after Shire withdrew its US application in 2012 over a demand for more controlled trials, even as a 2009 Fabrazyme shortage sent roughly 700 patients worldwide switching onto it instead. Pozelimab (Veopoz) extends this site's complement-C5 antibody cluster to a fourth entrant, approved 2023 for CHAPLE disease — an inherited complement disorder so ultra-rare that fewer than 10 US patients had been identified at approval, and the FDA accepted a 10-patient, single-arm trial with no placebo group as its entire evidence base. Rozanolixizumab (Rystiggo) is a second FcRn-blocking antibody for generalized myasthenia gravis alongside efgartigimod, approved 2023 — the first FDA-approved gMG treatment covering both AChR- and MuSK-antibody-positive patients from its original approval, and since expanded to real at-home self-administration in the EU and Japan. The Library now stands at 202 ingredient pages.

3 new Library pages: the GnRH antagonist that came before degarelix, a gonadotropin never approved in the US, and the newest hereditary angioedema drug — September 16, 2026

Abarelix (Plenaxis) was the first GnRH antagonist ever approved for prostate cancer, in 2003 — years before this site's own degarelix page — but came with a mandatory allergic-reaction-monitoring program from day one and was discontinued from US sale by 2005. Corifollitropin alfa (Elonva) completes this site's gonadotropin cluster: a hybrid FSH-hCG molecule whose single injection replaces the first seven days of daily FSH shots in IVF, EU-approved since 2010 across more than 75 countries, but never approved by the FDA after a 2014 rejection. Sebetralstat (Ekterly) fills the one remaining gap in this site's hereditary angioedema cluster — approved 3 July 2025 as the first oral, on-demand pill for treating an HAE attack already underway, on the largest clinical trial ever run for the condition. The Library now stands at 205 ingredient pages.

2 new Library pages complete the Fabry and Pompe enzyme clusters: Elfabrio and Nexviazyme — September 15, 2026

Pegunigalsidase alfa (Elfabrio, 2023) is a third distinct Fabry disease enzyme, and a genuinely different one: grown in cultured plant cells rather than animal cells, then PEGylated for a longer circulating half-life, its head-to-head BALANCE trial tested it against the first approved Fabry enzyme (agalsidase beta) rather than placebo, and its original 2021 application was rejected solely over a COVID-blocked inspection of its Israeli manufacturing plant. Avalglucosidase alfa (Nexviazyme, 2021) is a second-generation Pompe disease enzyme engineered with substantially more of the uptake tag muscle cells use to absorb it, approved for adults on priority review after a head-to-head trial against the original Pompe enzyme — its maker is only now, in 2026, preparing to seek US approval for infants, five years after Europe already covered both age groups. The Library now stands at 161 ingredient pages.

New: is Mounjaro or Wegovy covered by the PBS in Australia? — September 15, 2026

Ozempic has been PBS-subsidised for type 2 diabetes since 2020, but the other two GLP-1 drugs are both stuck a year into their own PBS bids. Wegovy's obesity listing was recommended in November 2025 and publicly backed by the Health Minister in January 2026, yet price talks with Novo Nordisk are still unresolved. Mounjaro's diabetes listing went further still: recommended by the government's own advisory committee in March 2026 after three earlier knockbacks, then abandoned by manufacturer Eli Lilly weeks later over price and funding-cap terms, leaving an estimated 450,000 diabetics without subsidised access.

Semaglutide's UK page adds a second indication: MASH, and a NICE queue behind it — September 15, 2026

Separately from the weight-management approvals already on this page, the MHRA licensed injectable Wegovy for MASH (liver fibrosis short of cirrhosis) on 3 July 2026 — conditionally, with further trial data still required. The FDA had approved the identical indication in the US nearly eleven months earlier. NICE opened its own technology appraisal for this specific indication in November 2025, before the UK licence even existed, and it remains in development with no NHS funding route yet.

3 new Library pages complete an Fc-fusion decoy-receptor cluster: Sotatercept, Etanercept and Aflibercept — September 15, 2026

Sotatercept (Winrevair, 2024) is the first FDA-approved drug in a new class, activin signaling inhibitors, for pulmonary arterial hypertension — its pivotal STELLAR trial cut the risk of death or clinical worsening by 84%, and a second trial, ZENITH, expanded the label in October 2025 to the highest-mortality-risk patients. Etanercept (Enbrel, 1998) was one of the first TNF-blocker biologics ever approved, and is now a textbook patent-thicket case: two FDA-approved US biosimilars have existed since 2016 and 2019 without ever reaching a single American patient, blocked by patents that don't expire until 2029, a fight Sandoz escalated into a fresh antitrust lawsuit against Amgen in April 2025. Aflibercept (Eylea, Eylea HD and Zaltrap) is one VEGF-trap fusion protein sold as three separate approved drugs since 2011 — and the subject of a live, multi-front biosimilar patent war, with one biosimilar (Amgen's Pavblu) already on the market at risk while four others remain blocked or delayed by settlement into 2026 and 2027. The Library now stands at 164 ingredient pages.

Semaglutide and tirzepatide pages add a rare eye-disorder signal: NAION, reviewed by the EU, UK and Australia — September 15, 2026

Since mid-2025, the EU's EMA, the UK's MHRA and Australia's TGA have each reviewed a rare vision-loss condition (NAION) linked to semaglutide, updating labels or issuing safety alerts before the FDA added an equivalent US warning. Australia went further, asking whether the signal extended to tirzepatide too — its Advisory Committee on Medicines concluded in October 2025 that current evidence doesn't support that, though its own adverse-event database still held 10 tirzepatide-linked reports when the alert was finally published in July 2026.

3 new Library pages complete a thrombolytic cluster: Alteplase, Reteplase, and Tenecteplase — September 15, 2026

Alteplase (Activase, 1987) is the original recombinant tissue plasminogen activator, approved for heart attack, then pulmonary embolism, then acute ischemic stroke in 1996 on the landmark NINDS trial — its own FDA stroke label still stops at 3 hours even though AHA/ASA guidance has endorsed treating out to 4.5 hours for over a decade. Reteplase (Retavase, 1996) is alteplase re-engineered for simpler two-bolus dosing; its own pivotal GUSTO-III trial never showed a survival edge over alteplase for heart attack, but a 1,412-patient 2024 Chinese trial (published in NEJM) found it actually beats alteplase for a disease it isn't approved to treat in the US at all: acute ischemic stroke. Tenecteplase (TNKase, 2000) is a third engineered tPA variant built for a single five-second bolus — approved for heart attack on the 17,000-patient ASSENT-2 trial, then, after years of guideline-endorsed off-label stroke use, approved for acute ischemic stroke in March 2025, reported as the first new FDA-approved stroke medicine in nearly 30 years. The Library now stands at 167 ingredient pages.

3 new Library pages complete a first-generation thrombolytic cluster: Streptokinase, Urokinase and Anistreplase — September 15, 2026

Streptokinase (Streptase, 1977) was the original clot-buster, its mortality benefit established by two landmark 1980s trials (GISSI-1 and ISIS-2) — but it's a foreign bacterial protein, not a human enzyme, and it's no longer sold in the US or Canada, losing out once an accelerated tPA dosing regimen beat it on survival in 1993. Urokinase (Abbokinase, later Kinlytic, 1978) is a genuine human enzyme with an unusually turbulent regulatory history: pulled from the US market in 1999 after inspectors found its manufacturer hadn't adequately screened the human kidney cells used to make it for hepatitis and other contamination, reapproved in 2002 with a narrower label, and off the US market again as of this review, with a funded plan by Microbix Biosystems and Sequel Pharma targeting a 2028 comeback. Anistreplase (Eminase, 1989) is streptokinase chemically re-engineered into a single-bolus drug, roughly halving 30-day mortality against placebo in its pivotal trial, before bolus-dosed tPA drugs offered the same convenience without streptokinase's antigenicity and displaced it from the market entirely. The Library now stands at 170 ingredient pages.

Update: Australia's retatrutide page adds real 2026 harm cases — liver toxicity, and a product that wasn't retatrutide at all — September 15, 2026

Since January 2026, Victoria's health department has logged at least seven hospitalizations for acute liver toxicity in people who used a product sold online as "retatrutide" — a drug not approved anywhere and still a year or more from any legitimate market. A separate case disclosed by the TGA in September 2026 was worse in a different way: a patient suffered a near-fatal torn oesophagus from uncontrollable vomiting, and lab testing of the product afterward found no retatrutide in it at all — just an undeclared dose of semaglutide roughly eight times the concentration found in legitimate semaglutide products. No seller has been named in either case.

New comparison page: semaglutide vs tirzepatide, including the 2025 head-to-head trial — September 15, 2026

A real head-to-head trial (SURMOUNT-5) now exists comparing the two drugs directly rather than across separate placebo trials: tirzepatide produced 20.2% mean weight loss at 72 weeks versus 13.7% for semaglutide. The new page also compares UK, Australia, Canada and US insurance/public-coverage status side by side — coverage for both remains inconsistent in ways that don't track the efficacy gap.

New methodology page: anonymous-aggregate review vs the affiliate-embedded vendor-directory model — September 15, 2026

A generic, no-named-party explainer on why this site's Register uses a published, no-pay-to-rank standard with aggregate-only findings for failing categories, contrasted with the affiliate-embedded vendor-directory model common elsewhere in this market. Also strengthened the existing "no ads, no affiliate links, no vendor payment" disclosure across Library pages, the Register, and the Standard page.

Update: the certificate-of-analysis page now covers why reviews can't substitute for checking one yourself — September 15, 2026

A new section cites the FTC's 2024 rule against fake and undisclosed reviews, and the community-documented pattern of vendors seeding reviews or disputing negative ones in peptide-buyer forums, as the reason a review count or forum reputation is circumstantial at best next to an actual batch-linked COA.

Correction: the Register's public stat row was out of date, again — September 15, 2026

"Products assessed" and the topical-category checked-count on the Register page had drifted from the real ledger across several assessment rounds. Corrected from 160 to 172 products assessed overall, and from 65 to 85 products checked across the five topical categories that still have zero passing brands. No result changed — this was a stale total, not a re-assessment.

Correction: TB-500's legal-status section had the July 2026 FDA vote backwards — September 15, 2026

The TB-500 page previously said it "sits on FDA's Category 2 restricted-compounding list" and was reviewed "without a recommendation for inclusion" at the July 2026 advisory committee meeting. Both statements were wrong: TB-500 was removed from Category 2 in April 2026 along with BPC-157 and ten other peptides, and it was one of six peptides the committee actually recommended for compounding eligibility on 23 July 2026 (8-6, one abstention) — the same outcome as BPC-157. Corrected and re-sourced against independent law-firm and trade-press coverage of the vote.

New comparison page: BPC-157 vs TB-500 — September 15, 2026

The two most commonly stacked "healing peptides" have moved through identical legal-status milestones since April 2026 — but their human-evidence records aren't the same. BPC-157 now has three small, uncontrolled human pilot studies (2024-2025); the molecule actually sold as "TB-500" has never appeared in a published human study of its own at all.

New comparison page: CJC-1295 vs Ipamorelin — September 15, 2026

Both growth-hormone secretagogues were rejected by FDA's Pharmacy Compounding Advisory Committee within six weeks of each other in late 2024 — but for different reasons. Ipamorelin's rejection cited insufficient safety/efficacy evidence; CJC-1295's cited an actual nonclinical toxicity signal and an unresolved cardiac-safety question from a terminated 2006 trial.

2 new Library pages: Plerixafor and Sutimlimab — September 15, 2026

Plerixafor (Mozobil) completes the CXCR4-antagonist cluster alongside Motixafortide — the original 2008-approved stem-cell mobilizer, discovered by accident as an anti-HIV drug, now generic. Sutimlimab (Enjaymo) completes the complement-inhibitor cluster with a genuinely different mechanism from this site's C1-inhibitor-replacement HAE drugs: the first approved treatment for cold agglutinin disease, blocking a single downstream enzyme instead. The Library now stands at 172 ingredient pages.

3 new international pages: how the UK, Canada and EU actually classify a peptide — September 15, 2026

New country-prefixed pages fill a gap this site's existing enforcement-action indexes didn't cover: the underlying legal test each regulator applies, not just the resulting cases. The UK page covers the Human Medicines Regulations 2012's function/presentation test and the narrow "specials" exemption; the Canada page covers why an injectable peptide is legally barred from ever holding a Natural Health Product licence; the EU page covers the harmonised medicinal-product definition alongside the separate, EU-wide Novel Food authorisation gate, including a real peptide-adjacent product (serrapeptase) that failed it in January 2025.

Spain joins the EU GLP-1 reimbursement comparison — three rejections, and Mounjaro shut out too — September 15, 2026

Spain's Comisión Interministerial de Precios de los Medicamentos rejected Wegovy's obesity-indication reimbursement three separate times in 2025 (July, September, October) on budgetary grounds, then in the same December 2025 round also refused to widen Ozempic's diabetes reimbursement to a broader group and withheld any funding from Mounjaro at all. Spain has since cut the price of the diabetes drugs it already funds (Ozempic, Rybelsus) and Novo Nordisk separately cut Wegovy's private price in March 2026 — but the obesity indication remains entirely patient-paid. Added as an eleventh country on this site's EU GLP-1 reimbursement comparison table.

Update: Australia made unapproved peptides a 2026 enforcement priority — September 14, 2026

The TGA formally added unapproved peptide products to its compliance priorities in June 2026, and two enforcement operations have followed — an eight-month Australian Border Force/TGA/Victoria Police case and a New South Wales search-warrant case tied to a social media seller. Neither has produced a named party yet, so neither appears in the named-cases table; both are noted as open, same as the UK's ongoing Northampton investigation.

Update: Mounjaro access isn't one UK system — Scotland, Wales and Northern Ireland added — September 14, 2026

The Tirzepatide page's NHS section covered NHS England only. Added: Scotland's SMC approved it first (June 2024, a lower BMI floor than NICE later set), Wales paused a planned move to GP-level prescribing and now restricts it to specialist services with waiting lists reported in years in parts of the country, and Northern Ireland's own weight-management service doesn't launch until autumn 2026.

2 new Library pages: the third once-weekly growth hormone, and a first-in-class antibody-fragment drug — September 14, 2026

Somatrogon (Ngenla) completes this site's once-weekly growth hormone trio alongside lonapegsomatropin and somapacitan — a third distinct chemistry, approved in Canada well before the FDA, and still pediatric-only after its own adult trial missed its primary endpoint. Efgartigimod (Vyvgart) is a first-in-class engineered antibody fragment that treats generalized myasthenia gravis by clearing out disease-driving antibodies wholesale, a different mechanism than zilucoplan's complement blockade — approved 2021, then expanded into CIDP (2024) and every gMG antibody subtype (May 2026). The Library now stands at 132 ingredient pages.

2 new Library pages: the first once-weekly insulin, and a stem-cell mobilization peptide — September 14, 2026

Insulin Icodec (Awiqli) is the first once-weekly basal insulin approved anywhere, using the same reversible-albumin-binding trick as somapacitan — approved in Switzerland, Canada and the EU in 2024, rejected by the FDA that same year over manufacturing questions, and finally cleared in the US in March 2026 for type 2 diabetes only, after an advisory committee voted against it for type 1. Motixafortide (Aphexda) is a cyclic peptide CXCR4 antagonist that fixes a real stem-cell-collection bottleneck for multiple myeloma transplant patients — 92.5% hit the collection target on it plus G-CSF versus 26.2% on placebo in its pivotal trial, FDA-approved 2023. The Library now stands at 134 ingredient pages.

2 new Library pages: a long-acting insulin's regulatory saga, and a China-approved drug already targeted by US enforcement — September 14, 2026

Insulin Degludec (Tresiba) completes this site's insulin cluster with a genuinely different chemistry (a self-assembling multihexamer depot) and a real regulatory fight: a 2013 FDA rejection over a cardiovascular signal, a dedicated 7,637-patient outcomes trial, and a Danish fine over how the rejection was disclosed. Mazdutide is a real dual GLP-1/glucagon agonist approved in China (2025) on strong Phase 3 data — not approved anywhere in the West, and already the specific substance named in four of this site's own 2026 FDA warning-letter entries to unauthorized US sellers. The Library now stands at 136 ingredient pages.

Update: the UK licensed a Wegovy pill in June 2026 — it isn't an NHS drug yet — September 14, 2026

The Semaglutide page had no UK section at all. Added: the MHRA's 11 June 2026 licence for a once-daily oral semaglutide tablet for weight management, available only by private prescription so far, and why an NHS decision is a separate step that hasn't started — NICE has only listed a future appraisal for the tablet, with no timeline set, and its own review of the injectable version took about 18 months to reach a recommendation after that drug's UK licence.

New Library page: what "Research Use Only" actually means — September 14, 2026

A new explainer traces the RUO label back to its real source (an FDA in vitro-diagnostic reagent category, 21 CFR 809.10) and walks through why that has nothing to do with an injectable sold direct to a consumer — including FDA's own stated purity/immunogenicity reasoning for restricting BPC-157's compounding in 2023, and documented outbreaks from contaminated injectables as a concrete illustration of what "no sterility oversight" actually costs. This is a reference page, not an ingredient entry, so it doesn't move the Library's ingredient-page count.

Correction: the Register's public stat row was out of date — September 14, 2026

"Products assessed" and the topical-category checked-count on the Register page hadn't been updated since four assessment rounds ago. Corrected from 139 to 150 products assessed overall, and from 52 to 65 products checked across the five topical categories that still have zero passing brands. No result changed — this was a stale total, not a re-assessment.

2 new Library pages: a GLP-1 that never made it to market, and a growth-hormone drug living a second life under a different name — September 14, 2026

Taspoglutide had real, adequately-powered Phase 3 efficacy data across eight trials and 6,000+ patients — then Roche halted all dosing in 2010 over a hypersensitivity/anaphylaxis signal, and no country ever approved it. Ibutamoren (MK-677) isn't a peptide at all: Merck's own 2011 hip-fracture trial was stopped early after a heart-failure signal, ending adult development — but the same molecule is now in an actively-recruiting Phase 3 trial for pediatric growth hormone deficiency, under a different name and sponsor, using a biomarker test to select likely responders. The Library now stands at 138 ingredient pages.

Update: Canada came close to covering Wegovy nationally in 2025 — then Novo Nordisk walked away — September 14, 2026

The Canada insurance-coverage page said public plans simply don't cover Wegovy for weight loss; added the fuller story. Canada's Drug Agency formally recommended reimbursing it in July 2025 for a narrower cardiovascular-risk population, conditional on a steep price cut. The pan-Canadian Pharmaceutical Alliance sent Novo Nordisk a letter of engagement that October, the company declined to negotiate at all, and the file closed in December 2025 with no offer ever exchanged.

3 new Library pages: one peptide with three real FDA approvals, one that never got even one, and one grown in rabbits' milk — September 14, 2026

Pegcetacoplan is a single active ingredient approved three separate times for three unrelated diseases (2021, 2023, 2025) — including a real post-marketing retinal-vasculitis signal in the eye-injection formulation that led to a label update seven months after that approval. Serelaxin, by contrast, never reached market anywhere: its first Phase 3 trial found a striking mortality reduction, an FDA advisory committee still voted 11-0 against approval over a single trial's secondary finding, and the larger confirmatory trial regulators required came back negative. Conestat alfa completes this site's hereditary-angioedema cluster alongside icatibant and ecallantide — an FDA-approved acute-attack treatment purified from transgenic rabbits' milk, whose 2018 attempt to also win approval as a preventive treatment was rejected and never revived. The Library now stands at 141 ingredient pages.

2 new Library pages: the original HAE plasma drugs, and Botox's real regulatory history — September 14, 2026

Berinert and Cinryze complete this site's hereditary-angioedema cluster: the two original plasma-derived C1 esterase inhibitor replacement drugs, approved a year apart for opposite jobs — Cinryze (2008) for routine prevention, Berinert (2009) for treating an attack already underway — each backed by its own placebo-controlled pivotal trial. Botulinum toxin gets its own page for the first time: a real, 1989-approved protein drug with a dozen-plus indications across five branded products, plus two separate CDC-documented episodes — a 2024 counterfeit-injection outbreak and a 2025 report of people self-injecting product bought online — that are about unauthorized sourcing, not the approved drug's own safety record. The Library now stands at 143 ingredient pages.

3 new Library pages: a Gaucher disease drug crisis, its two rivals, and a gout enzyme's rocky corporate history — September 14, 2026

Imiglucerase (Cerezyme) was the standard Gaucher disease enzyme-replacement drug for 15 years — until a 2009 virus contamination shut down its only factory, triggering a shortage that lasted into 2012, a $175 million FDA consent-decree penalty, and Genzyme's own $20.1 billion sale to Sanofi. That shortage fast-tracked two rival drugs onto the market, covered together on a companion page: velaglucerase alfa (VPRIV), grown in a human cell line, and taliglucerase alfa (Elelyso), the first plant-cell-expressed recombinant protein drug the FDA had ever approved — both drugs kept meaningful market share even after Cerezyme's supply normalized. Pegloticase (Krystexxa) restores an enzyme humans lost through evolution to treat severe gout, but most patients develop antibodies against its PEG coating that stop it working and raise infusion-reaction risk — a real 2022 FDA approval of co-administered methotrexate, tested in a randomized trial, roughly doubles the durable response rate. The Library now stands at 146 ingredient pages.

2 new Library pages: the two other Genzyme lysosomal-storage-disease drugs hit by the 2009 crisis — September 14, 2026

Agalsidase beta (Fabrazyme) was FDA-approved in 2003 for Fabry disease and went through the same 2009 Genzyme plant contamination as Cerezyme — but Fabry patients had no alternative and were rationed to about 30% of their approved dose for nearly three years; its accelerated approval wasn't converted to a full one until 2021, closing off that pathway for at least one competing gene-therapy candidate. Alglucosidase alfa (Myozyme, later also Lumizyme) turned previously fatal infantile-onset Pompe disease into a treatable one starting in 2006 — then was approved a second time under a different brand name in 2010 because a larger manufacturing scale counted as a new product to the FDA, with an age-restricted program not lifted until 2014. The Library now stands at 148 ingredient pages.

3 new Library pages: the two other lysosomal-storage-disease enzymes, plus a fourth Pompe drug with a genuinely nuanced trial record — September 14, 2026

Laronidase (Aldurazyme) was the first approved treatment for MPS I in 2003 — a unanimous FDA advisory-committee vote still wasn't enough to avoid a further three-month delay over manufacturing and labeling issues, and the drug reached market through an unusual 50/50 joint venture between BioMarin and Genzyme rather than one company alone. Idursulfase (Elaprase) opens a companion MPS II (Hunter syndrome) page: a real 2006 enzyme-replacement approval that cannot cross the blood-brain barrier, whose decade-long attempt at an injected-into-the-spine version aimed at the disease's cognitive effects failed its pivotal trial in 2017 and was formally discontinued by Takeda in 2022. Cipaglucosidase alfa (Pombiliti plus Opfolda) completes this round: a fourth distinct Pompe disease enzyme whose own pivotal trial missed its primary endpoint for statistical significance in the overall population, approved anyway on secondary and subgroup evidence in patients already switching from an existing therapy — and whose FDA review was separately delayed a full year in 2022 not by any of that trial data, but by COVID-era travel restrictions blocking a required inspection of a Chinese manufacturing site. The Library now stands at 151 ingredient pages.

Italy joins the EU GLP-1 reimbursement comparison — a world-first obesity law with no reimbursement to show for it yet — September 14, 2026

Italy passed the world's first dedicated national obesity law in October 2025, formally recognizing obesity as a chronic disease and opening a path toward folding its treatment into the national health service's covered services. Nearly a year later, that path hasn't reached a prescription: Wegovy and Mounjaro both remain fully patient-paid for the obesity indication, and the country's bariatric-surgery society publicly pressed the government this month to issue the law's outstanding implementing decrees. Added as a ninth country on this site's EU GLP-1 reimbursement comparison table.

Update: a fourth named UK action, this time against a licensed pharmacy — September 14, 2026

A February 2026 MHRA Drug Safety Update confirmed falsified Mounjaro pens reached patients through a Birmingham pharmacy, The Private Pharmacy Clinic, after which the General Pharmaceutical Council barred it from obtaining, selling or supplying any prescription-only medicine while its own investigation continues — a different enforcement mechanism than the three already on this site's UK actions page (a criminal prosecution, a Trading Standards seizure, and a High Court website-blocking order).

3 new Library pages complete the insulin-analog cluster: lispro, aspart, and glargine — September 14, 2026

Insulin lispro (Humalog, 1996) was the first insulin analog ever approved — and became the drug most closely tied to the US insulin-pricing crisis, from a $21 launch price to a 26-year-old's 2017 rationing death that helped drive Minnesota's first-in-the-nation insulin-access law. Insulin aspart (NovoLog/Fiasp, 2000) was the second rapid-acting analog, and is now the first insulin on this site with real 2025 biosimilar competition: Merilog (February 2025) as the first rapid-acting insulin biosimilar ever approved, then Kirsty (July 2025) as the first one designated interchangeable. Insulin glargine (Lantus/Toujeo, 2000) solved the opposite problem — a once-daily basal insulin that precipitates under the skin instead of dissolving faster — and its patent litigation against Eli Lilly and Merck genuinely shaped which competing products reached the US market and when. The Library now stands at 154 ingredient pages.

2 new Library pages complete a protein-enzyme cluster: Dornase Alfa and Rasburicase — September 14, 2026

Dornase alfa (Pulmozyme, 1993) succeeded where a 1958 bovine-derived version of the same idea had failed: a genetically engineered copy of the human enzyme, rather than a foreign animal protein, thins the DNA-thickened mucus in cystic fibrosis lungs without the allergic reactions that doomed its predecessor — and more than a decade after its US patents expired, it still has no FDA-approved biosimilar. Rasburicase (Elitek, 2002 pediatric / 2009 adult) restores a different enzyme humans lost through evolution — uricase — to rapidly clear the uric acid surge of tumor lysis syndrome, a genuine cancer-treatment emergency, but its label carries three boxed warnings including a real risk of severe hemolysis in patients with undiagnosed G6PD deficiency, and real-world hospital practice has since shifted toward off-label doses well below what the original FDA label specifies. The Library now stands at 156 ingredient pages.

3 new Library pages complete the MPS enzyme-replacement cluster: Vimizim, Naglazyme and Mepsevii — September 14, 2026

Elosulfase alfa (Vimizim, 2014) was the first treatment for MPS IVA (Morquio A syndrome) — a real placebo-controlled trial found the FDA-approved weekly dose worked while a second, every-other-week dose tested in the same trial produced no benefit over placebo, and a roughly $380,000 annual list price only reached UK patients through a five-year NHS managed-access deal struck in 2015. Galsulfase (Naglazyme, 2005) was the first treatment for MPS VI (Maroteaux-Lamy syndrome), backed by a genuine placebo-controlled walking-distance win, later extended with a dedicated study supporting its use in infants as young as three months. Vestronidase alfa (Mepsevii, 2017) completes the cluster for MPS VII (Sly syndrome) — a disease with perhaps 200 known patients worldwide, developed by Ultragenyx rather than the BioMarin behind the other two, using an unusual 'blind start' trial design built specifically for a population too small for a conventional randomized trial. The Library now stands at 159 ingredient pages.

4 new Library pages: Nafarelin, Desirudin, Lepirudin, Sargramostim — September 13, 2026

Nafarelin completes the nasal-spray branch of the GnRH-agonist cluster; Desirudin and Lepirudin round out the hirudin-derived anticoagulant family alongside Bivalirudin (both discontinued in the US, for different reasons); Sargramostim covers GM-CSF, including its unusual 2018 approval for radiation exposure based entirely on animal studies.

2 more Register assessments logged — September 13, 2026

Two more topical peptide products checked against the 11-point standard, bringing the Register to 139 total assessments (2 listed).

5 new Library pages: non-opioid pain and itch peptides, two diagnostic-only drugs, and a US regulatory outlier — September 13, 2026

Ziconotide (cone-snail venom, non-opioid chronic pain) and Difelikefalin (peripherally restricted, for hemodialysis itch) round out a small cluster of non-opioid peptide drugs; Macimorelin joins as a single-dose diagnostic test for adult growth hormone deficiency; Trofinetide is the first FDA-approved treatment for Rett syndrome; and Atosiban is a genuinely mainstream labor-delaying drug across the EU and Canada that the FDA has never approved, after a US trial's fetal-death signal. The Library now stands at 120 ingredient pages.

New: Health Canada context, and where it doesn't (yet) exist — September 13, 2026

Legal/approval statements on this site have always described the US specifically; that's now stated plainly on Our standard, along with a note that Health Canada context is being added only where a real, sourced divergence exists — not assumed. First additions: a Semaglutide note on Canada's 2026 generic approval (years ahead of the US, over a lapsed patent), and a new page indexing Health Canada's own public enforcement actions against unauthorized peptide sellers.

UK and Australia enforcement-actions pages added — September 13, 2026

Same pattern as the FDA and Health Canada pages, now for two more countries: a UK index (an MHRA criminal conviction, a Trading Standards seizure, and a High Court order forcing internet providers to block counterfeit-drug sites) and an Australia index (the TGA's October 2024 nationwide ban on compounding GLP-1-class medicines, two 2025 advertising-enforcement actions, and three named SARMs/peptide court cases since 2022).

Tirzepatide and Semaglutide: UK and Australia drug-access context added — September 13, 2026

New sections cover how NHS England actually rations Mounjaro access by BMI and comorbidity tier rather than by insurance status, and where Australia's Wegovy stands in its still-unresolved PBS subsidy process a year after it recommended listing.

2 new Canada pages: insurance coverage, and a compounding loophole — September 13, 2026

A plain explainer on what Canadian public and private drug plans actually cover for semaglutide/tirzepatide (diabetes: usually yes, with conditions; weight loss: usually no) and what it costs either way — plus a page on a real regulatory gap a 2026 CBC investigation found: a compounding-pharmacy exemption being used to prescribe BPC-157, a peptide Health Canada has not approved as a drug.

New: France becomes the first EU country to reimburse Wegovy and Mounjaro — September 13, 2026

Since 15 June 2026, French national health insurance covers both drugs for severe obesity (BMI 40+, or 35+ with a comorbidity) — but only a specialist can write the first reimbursable prescription, not a GP. A comparison table covers how Germany, the Netherlands and Denmark treat the same question differently.

New: Belgium's GLP-1 coverage picture — a reimbursement 'no' and a fraud crackdown — September 13, 2026

Belgium declined to reimburse Wegovy for obesity on 3 June 2026, following a negative opinion from INAMI's own reimbursement commission. Separately, since 1 February 2026, the long-established diabetes-indication reimbursement for Ozempic and Mounjaro now requires prior insurer authorization, after INAMI's own figures showed a spending surge it attributes largely to fraudulent and off-label claims.

Update: Poland joins the 'no' side of the EU GLP-1 reimbursement comparison — September 13, 2026

AOTMiT, Poland's health-technology assessment agency, recommended against reimbursing Mounjaro for obesity in June 2026 over durability-of-effect and NFZ budget concerns — not efficacy. A Wegovy obesity application remains pending. Added to the France reimbursement page's five-country comparison table.

3 new Library pages: a missing GnRH agonist, and two peptide/lipopeptide antimicrobial clusters — September 13, 2026

Buserelin completes the GnRH-agonist cluster alongside leuprolide, goserelin, triptorelin and nafarelin — decades-old and widely used in Europe and Canada, but never submitted for FDA approval. Teicoplanin covers vancomycin's Cochrane-reviewed, less-nephrotoxic cousin, reviewed by an FDA panel in the 1990s and still not approved in the US. Echinocandins (Caspofungin, Micafungin, Anidulafungin) covers the antifungal mirror of daptomycin's antibacterial lipopeptide mechanism, including a real EU-only warning on one member that the FDA never matched. The Library now stands at 123 ingredient pages.

Update: Sweden rejects Wegovy for obesity, twice, in 2026 — September 13, 2026

TLV, Sweden's benefits agency, declined to subsidize Wegovy for adults in February 2026 — not disputing the drug's effectiveness but its own ability to keep prescribing inside the requested, high-BMI patient group — then rejected a narrower adolescents-only refiling again in July. Novo Nordisk is appealing the adult rejection in court. Added to the France reimbursement page's now six-country comparison table.

3 new Library pages: a calcimimetic, a radioactive cancer drug, and a peptide complement inhibitor — September 13, 2026

Etelcalcetide (Parsabiv) lowers parathyroid hormone in hemodialysis patients by the opposite mechanism from this site's PTH-analog drugs, backed by three Phase 3 trials in over 1,700 patients. Lutetium Lu 177 dotatate (Lutathera) takes the somatostatin-analog peptide behind octreotide and turns it into a radioactive cancer treatment — the first peptide-receptor radionuclide therapy ever approved, on the strength of a landmark NEJM trial. Zilucoplan (Zilbrysq) is a once-daily self-injected macrocyclic peptide that blocks complement C5, the same target as antibody drugs like eculizumab, approved in 2023 for generalized myasthenia gravis. The Library now stands at 126 ingredient pages.

2 new Library pages: the two once-weekly growth hormone products — September 13, 2026

Lonapegsomatropin (Skytrofa) and Somapacitan (Sogroya) both turn daily human growth hormone into a once-a-week injection, using two genuinely different chemical tricks — a slow-release prodrug versus reversible albumin binding. Skytrofa is approved for children (2021) and adults (2025); Sogroya is approved for adults (2020) and, as of February 2026, four separate pediatric growth-disorder indications. The Library now stands at 128 ingredient pages.

2 new Library pages: Insulin, and a surfactant drug that didn't survive commercially — September 13, 2026

Insulin was the first genetically-engineered drug ever approved (Humulin, 1982) and is now at the center of the biggest US peptide-drug pricing story of the last decade — a federal Medicare cap, a real interchangeable biosimilar, and 2025-2026 manufacturer pricing deals. Lucinactant (Surfaxin) was the first synthetic peptide-based lung surfactant approved (2012), a genuine scientific success that its maker still stopped selling in 2015 for commercial reasons. The Library now stands at 130 ingredient pages.

12 new Library pages: fertility hormones, lipoglycopeptide antibiotics, EPO/CSF drugs — September 12, 2026

Follitropin Alfa/Beta, Menotropins, Lutropin Alfa, Choriogonadotropin Alfa, and Thyrotropin Alfa join the fertility/diagnostic-hormone cluster; Telavancin, Dalbavancin, and Oritavancin cover the lipoglycopeptide antibiotics; Epoetin Alfa, Darbepoetin Alfa, Filgrastim, and Pegfilgrastim cover the erythropoietin and colony-stimulating-factor drugs. The Library now stands at 111 ingredient pages.

Correction: two duplicate Register assessments merged — September 12, 2026

Ancient Nutrition and Garden of Life's collagen-peptide products had each been independently assessed twice in separate research rounds without a duplicate check. Both duplicates have been merged into a single, more detailed entry, and the public "products assessed" count corrected down from 139 to 137.

Two standing automations now watch this site for us — September 12, 2026

A weekly pass re-checks Register categories for new or reassessment-due brands, and a separate weekly pass re-checks existing FDA warning-letter findings for status changes (closeout letters, new letters) — both land Sunday evening for Monday-morning review, and nothing publishes without a human check first.